Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 63, Issue 12, 2002, Pages 1140-1147

  Spencer, Thomas ^a   Heiligenstein, John H ^a   Biederman, Joseph ^a   Faries, Douglas E ^a   Kratochvil, Christopher J ^a   Keith Conners, C ^a   Potter, William Z ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGGRESSION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; NORADRENALIN UPTAKE; OUTCOMES RESEARCH; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SCORING SYSTEM; SOMNOLENCE; THORAX PAIN; TIC; VOMITING;

EID: 0036935774     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1209     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000
2. Jensen PS, Kettle L, Roper MT, et al. Are stimulants overprescribed? treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999;38:797-804
3. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-1170
4. Robison LM, Sclar DA, Skaer TL, et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr 1999;38:209-217
5. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279:1100-1107
6. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086
7. Spencer TJ, Biederman J, Wilens TE, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432
8. Green W. The treatment of attention deficit hyperactivity disorder with nonstimulant medications. Child Adolesc Psychiatr Clin North Am 1995;4:169-195
9. Greenhill L. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am 1995;4:123-168
10. Popper CW. Antidepressants in the treatment of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1997;58(suppl 14):14-29
11. Zametkin AJ, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998;59(suppl 7):17-23
12. Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cog Sci 1998;2:436-447
13. Pliszka SR, McCracken JT. Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35:264-272
14. Biederman J, Spencer TJ. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999;46:1234-1242
15. Mefford IN, Potter WZ. A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. Med Hypotheses 1989;29:33-42
16. Wolf CR, Smith G. Cytochrome P450 CYP2D6. Lyon, France: IARC Scientific Publications; 1999:209-229
17. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo-controlled study of desipramine in the treatment of ADD, 1: efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-784
18. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-265
19. Spencer TJ, Biederman J, Wilens TE, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-695
20. Wechsler D. Wechsler Intelligence Scale for Children (WISC-III). 3rd ed. San Antonio, Tex: The Psychological Corporation, Harcourt Brace and Company; 1991
21. Kaufman J, Birmaher B, Brent D, et al. Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Version 1.0 of October 1996 ed. Pittsburgh, Pa: The Department of Psychiatry, University of Pittsburgh School of Medicine; 1996
22. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretations. New York, NY: The Guilford Press; 1998
23. Novartis. Ritalin/Ritalin-SR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001
24. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Attention Disord 2001;5:39-47
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Bethesda, Md: US Dept Health, Education, and Welfare; 1976
26. Conners CK. Conners' Rating Scales: Revised Technical Manual. North Towanda, NY: Multi-Health Systems; 1997
27. Conners CK, Casat CD, Gualtieri CT. et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321
28. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39
29. Ghuman JK, Ginsburg GS, Subramaniam G, et al. Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution. J Am Acad Child Adolesc Psychiatry 2001;40:516-524
30. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153
31. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901